Overview

AMPLATZER™ DUCT OCCLUDERS
STRUCTURAL INTERVENTIONS

Designed for flexibility, our innovative duct occluder options conform to a variety of duct sizes while achieving complete patent ductus arteriosus (PDA) closure from a pulmonary or aortic approach.

SWITCH TO THE REFERRAL VIEW For more information specific to neonatology regarding PDA closure

INDUSTRY-LEADING AMPLATZER™ PDA OCCLUDERS¹

The Amplatzer™ family of patent ductus arteriosus (PDA) closure occluders provides proven closure for a wide variety of patient morphologies.²These devices share several Amplatzer™ characteristics:

Provide secure positioning in the ductus
Achieve complete closure
Promote tissue in-growth
Provide flexibility and conformability

ABBOTT EVENTS

PremiClose is the only worldwide symposium focused on PDA closure in preterm infants. The goal of this event is to broaden PDA closure as a therapy in premature babies, and optimize the synergies between interventional pediatric cardiologists and neonatologists. Find out more about PremiClose's last edition in the section below.

3RD PREMICLOSE SYMPOSIUM 2022 (PDA)

Watch the recorded sessions of the latest edition of the PremiClose symposium, with world experts in interventional pediatric cardiology and neonatology discussing the latest developments in patent ductus arteriosus (PDA) closure in preterm infants.

The program includes technical and therapy-related topics aimed to improve outcomes by optimizing the synergy between interventionists and neonatologists.

WATCH ON DEMAND

CLICK BELOW TO WATCH YOUR SESSION OF INTEREST:

DOWNLOAD FULL AGENDA

After 10 years where are we now? Technical variations. Different ways to do it.

Moderators: Neil Wilson (GBR), Gianfranco Butera (ITA)

In the Cathlab “regular model” fluoroscopy & echocardiography

Jose Luis Zunzunegui (ESP)

In the NICU “American model”

Evan Zahn (USA)

In the NICU outside our own centre “German model”

Stanimir Georgiev (DEU)

What to do to limit complications? How to deal with complications? Establishing a decision-making protocol.

Moderators: Mara Pilati (ITA), Carles Bautista (ESP)

Device embolization

Alejandro Rodríguez (ESP)

Device protrusion and aortic and
pulmonary artery obstruction

Alain Fraisse (FRA)

Cardiovascular injury and ductus
spasm

Guiti Milani (FRA)

Clinical case presentations.

Moderators: Alain Fraisse (FRA), Peter Ewert (DEU)

Late complication after PDA closure

Micol Rebonato (ITA)

PDA closure in premature babies

Ahmed Alomrani (SAU)

What evidence do we have on early effect of transcatheter PDA closure? What do we know when comparing with surgery?

Moderators: Peter Ewert (DEU), Christian Jux (DEU)

Comparison of post-PDA ligation syndrome: surgery vs device closure

Ryan Alexy (USA)

Improved ventilation in premature babies after transcatheter vs surgical closure of patent ductus arteriosus

Alban-Elouen Baruteau (FRA)

Changes in cardiac physiology after PDA closure

Amir Ashrafi (USA)

What do we know on midterm evolution? What can we improve?

Moderators: Manuel Sánchez-Luna (ESP), Jose Luis Zunzunegui (ESP)

Fate of the pulmonary left artery and thoracic aorta, femoral vein, and myocardium after transcatheter…

Evan Zahn (USA)

Medium term clinical follow up after percutaneous closure (neurological and respiratory evolution)

Jean-Christophe Roze (FRA)

Some questions about the percutaneous closure of the preterm PDA “not everything is clear”.

Moderators: Yogen Singh (GBR), Alban-Elouen Baruteau (FRA)

Percutaneous PDA closure in preterms <1000 gr. Is it as safe as surgery?

Alain Fraisse (FRA)

Functional ultrasound performed by neonatologists in the preterm PDA.

Amir Ashrafi (USA)

I want to start with the percutaneous closure of the preterm PDA. Can I do it? Should I do it?

Bernd Opgen-Rhein (DEU)

Has my concept of invasive closure of PDA changed since we have the percutaneous approach?

Manuel Sánchez-Luna (ESP)

The content in these sessions represents the opinions of the participants and contributors to the symposium. Statements or clinical cases presented or discussed reflect the clinical judgement of the physicians. As a consequence, Abbott accepts no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither does Abbott endorse the content or the use of a device in a way that lies outside its current licensed application in any territory.

Connext
TV

CONNECT TO THE LATEST
IN STRUCTURAL HEART
THERAPY

Find out more

References

Data on file at Abbott.
Philip R, Waller BR III, Agrawal V et al. Morphologic characterization of the patent ductus arteriosus in the premature infant and the choice of transcatheter occlusion device. Catheter Cardiovasc Interv. 2016;87(2): 310–317. doi.org/10.1002/ccd.26287.
Schneider DJ, Moore JW. Patent ductus arteriosus. Circulation. 2006;114(17):1873-1882. doi.org/10.1161/CIRCULATIONAHA.105.592063.
Amplatzer Piccolo™ Occluder Instructions for Use.
Stout KK, Daniels CJ, Aboulhosn JA et al. 2018 AHA/ACC Guideline for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(14):e698–e800. doi.org/10.1161/CIR.0000000000000603.
Baruteau A-E, Hascoët S, Baruteau J et al. Transcatheter closure of patent ductus arteriosus: past, present and future. Arch Cardiovasc Dis. 2014;107(2):122–132.
doi.org/10.1016/j.acvd.2014.01.008.
Data on File, 302350-001_G Amplatzer™ Duct Occluder CER.
Saliba Z, El-Rassi I, Abi-Warde MT et al. The Amplatzer Duct Occluder II: a new device for percutaneous ductus arteriosus closure. J Interven Cardiol. 2009;22(6):496–502.
doi.org/10.1111/j.1540-8183.2009.00504.x.
Gruenstein DH, et al. Transcatheter closure of patent ductus arteriosus using the Amplatzer™ Duct Occluder II (ADO II). Catheter Cardiovasc Interv. 2017;89(6):1118-1128. doi.org/10.1002/ccd.26968.